This study reveals that the expression of VTN is diminished in pancreatic cancer and that its expression correlates with patient prognosis and the efficacy of immunotherapy, suggesting that VTN may serve as a potential prognostic biomarker and a sensitizer target for anti-PD1 treatment in pancreatic cancer. This evidence concerns the gene VTN and pancreatic neoplasm.